• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Executive Chairman Chan Heng Fai Ambrose

    1/28/25 9:36:07 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care
    Get the next $HWH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chan Heng Fai Ambrose

    (Last) (First) (Middle)
    C/O SHARING SERVICES GLOBAL CORPORATION
    5200 TENNYSON PARKWAY, SUITE 400

    (Street)
    PLANO, TX 75024

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SHARING SERVICES GLOBAL Corp [ SHRG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    Executive Chairman
    3. Date of Earliest Transaction (Month/Day/Year)
    01/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Convertible Promissory Note (1) 03/18/2024 P 148,810(1) 03/25/2025(1) 03/18/2027 Common Stock (1) $1.68(1) 148,810(1) I See footnote(6)
    Common Stock Purchase Warrant (1) 03/18/2024 P 148,810(1) 03/25/2025 03/18/2029 Common Stock (1) $1.68(1) 297,620(1) I See footnote(6)
    Convertible Promissory Note (2) 05/09/2024 P 89,286(2) 03/25/2025(2) 05/18/2027 Common Stock (2) $2.8(2) 386,906(2) I See footnote(6)
    Convertible Promissory Note (3) 06/06/2024 P 89,286(3) 03/25/2025(3) 06/06/2027 Common Stock (3) $2.8(3) 476,192(3) I See footnote(6)
    Convertible Promissory Note (4) 08/13/2024 P 35,714(4) 03/25/2025(4) 08/13/2027 Common Stock (4) $2.8(4) 511,906(4) I See footnote(6)
    Convertible Promissory Note (5) 11/12/2024 P 2,500,000(5) 03/25/2025(5) 11/12/2026 Common Stock (5) $0.1(5) 3,011,906(5) I See footnote(6)
    1. Name and Address of Reporting Person*
    Chan Heng Fai Ambrose

    (Last) (First) (Middle)
    C/O SHARING SERVICES GLOBAL CORPORATION
    5200 TENNYSON PARKWAY, SUITE 400

    (Street)
    PLANO, TX 75024

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    X Director X 10% Owner
    Officer (give title below) X Other (specify below)
    Executive Chairman
    1. Name and Address of Reporting Person*
    Alset Inc.

    (Last) (First) (Middle)
    4800 MONTGOMERY LANGE, SUITE 210

    (Street)
    BETHESDA, MD 20814

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    HWH International Inc.

    (Last) (First) (Middle)
    4800 MONTGOMERY LANE, SUITE 210

    (Street)
    BETHESDA, MD 20814

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On March 18, 2024, the Issuer entered into a Convertible Promissory Note (the "March Note") promising to pay HWH International Inc., a Delaware corporation ("HWH"), $250,000.00. All amounts due under the March Note may be converted into the common stock of the Issuer at the discretion of the holder. The conversion price is fixed at $1.68 per share. The Issuer and HWH subsequently entered into an amendment to the March Note which set the term of the optional conversion feature of the March Note to be between March 25, 2025, and the maturity of the Note on the third anniversary of its effectiveness, March 18, 2027. As further consideration for the March Note, the Issuer granted HWH a common stock purchase warrant to purchase up to 148,810 shares of the Issuer's common stock at a purchase price of $1.68 per share.
    2. On May 9, 2024, the Issuer entered into a Convertible Promissory Note (the "May Note") promising to pay HWH $250,000.00. All amounts due under the May Note may be converted into the common stock of the Issuer at the discretion of the holder. The conversion price is fixed at $2.80 per share. The Issuer and HWH subsequently entered into an amendment to the May Note which set the term of the optional conversion feature of the May Note to be between March 25, 2025, and the maturity of the Note on the third anniversary of its effectiveness, May 9, 2027.
    3. On June 6, 2024, the Issuer entered into a Convertible Promissory Note (the "June Note") promising to pay HWH $250,000.00. All amounts due under the June Note may be converted into the common stock of the Issuer at the discretion of the holder. The conversion price is fixed at $2.80 per share. The Issuer and HWH subsequently entered into an amendment to the June Note which set the term of the optional conversion feature of the June Note to be between March 25, 2025, and the maturity of the Note on the third anniversary of its effectiveness, June 6, 2027.
    4. On August 13, 2024, the Issuer entered into a Convertible Promissory Note (the "August Note") promising to pay HWH $100,000.00. All amounts due under the August Note may be converted into the common stock of the Issuer at the discretion of the holder. The conversion price is fixed at $2.80 per share. The Issuer and HWH subsequently entered into an amendment to the August Note which set the term of the optional conversion feature of the August Note to be between March 25, 2025, and the maturity of the Note on the third anniversary of its effectiveness, August 13, 2027.
    5. On November 12, 2024, the Issuer entered into a Convertible Promissory Note (the "November Note") promising to pay Alset Inc., a Texas corporation, $250,000.00. All amounts due under the November Note may be converted into the common stock of the Issuer at the discretion of the holder. The conversion price is fixed at $0.10 per share. The Issuer and Alset Inc. subsequently entered into an amendment to the November Note which set the term of the optional conversion feature of the November Note to be between March 25, 2025, and the maturity of the Note on the second anniversary of its effectiveness, November 12, 2026.
    6. Mr. Chan is the Chairman, Chief Executive Officer and majority stockholder of Alset Inc. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc. Mr. Chan is the Chairman of HWH International Inc., which is a majority-owned subsidiary of Alset Inc. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by HWH International Inc.
    HWH International Inc. /s/ Ronald Wei, Chief Financial Officer 01/28/2025
    Alset Inc. /s/ Chan Heng Fai Ambrose, Chief Executive Officer 01/28/2025
    /s/ Chan Heng Fai Ambrose 01/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HWH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HWH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HWH
    SEC Filings

    See more
    • SEC Form 10-Q filed by HWH International Inc.

      10-Q - HWH International Inc. (0001897245) (Filer)

      5/15/25 4:16:04 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form SCHEDULE 13G filed by HWH International Inc.

      SCHEDULE 13G - HWH International Inc. (0001897245) (Subject)

      5/14/25 4:42:18 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by HWH International Inc.

      10-K - HWH International Inc. (0001897245) (Filer)

      3/31/25 4:05:57 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Executive Chairman Chan Heng Fai Ambrose

      4 - HWH International Inc. (0001897245) (Reporting)

      4/2/25 8:37:43 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Director Chan Heng Fai Ambrose acquired 69,444 shares (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      3/13/25 4:15:07 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Executive Chairman Chan Heng Fai Ambrose

      4 - HWH International Inc. (0001897245) (Reporting)

      1/28/25 9:36:07 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HWH International Inc.

      SC 13D/A - HWH International Inc. (0001897245) (Subject)

      11/26/24 7:34:11 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by HWH International Inc.

      SC 13D/A - HWH International Inc. (0001897245) (Subject)

      11/22/24 5:00:10 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HWH International Inc.

      SC 13G/A - HWH International Inc. (0001897245) (Subject)

      11/14/24 12:40:52 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Heng Fai Ambrose bought $585,000 worth of shares (1,300,000 units at $0.45) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      12/26/24 5:15:05 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Director Chan Heng Fai Ambrose bought $3,000,000 worth of shares (4,411,764 units at $0.68) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      11/26/24 7:12:12 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Chan Heng Fai Ambrose bought $3,801,758 worth of shares (6,034,537 units at $0.63) (SEC Form 4)

      4 - HWH International Inc. (0001897245) (Issuer)

      9/26/24 9:39:51 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HWH International Inc. Announces Reverse Stock Split

      BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced a 1-for-5 reverse stock split of the Company's common stock to become effective at 9:00 a.m. (Eastern Time) on February 24, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 24, 2025, under the existing trading symbol "HWH." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 448

      2/20/25 8:50:00 AM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

      BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,900, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,412,500 shares of common stock and 1,000,000 pre-funded warrants to purchase 1,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded

      1/7/25 11:18:56 AM ET
      $HWH
      Other Pharmaceuticals
      Health Care
    • HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share

      BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,875, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,125,000 shares of common stock and 1,250,000 pre-funded warrants to purchase 1,250,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded w

      1/6/25 4:20:00 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care

    $HWH
    Financials

    Live finance-specific insights

    See more
    • HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet

      Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. ("HWH") (NASDAQ:HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in South Korea. HWH is delighted to reveal its latest acquisition of a café nestled in the heart of Seocho-gu, South Korea. This strategic move signifies HWH's dedication to providing unique and welcoming spaces where people can gather to savor food, coffee, and experiences. These cafes are a significant driver of our Health, Wealth, and Happiness vision to offer delicious and nutritious food and beverages to our customers and provide a platform where we can roll out lifestyle pr

      2/26/24 4:15:00 PM ET
      $HWH
      Other Pharmaceuticals
      Health Care